Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
At 2 mg/mL, the 2.4 mg maintenance dose requires 1.2 mL, which exceeds a standard 1 mL insulin syringe
only occasional peaks should approach max values
35 Alpha-Glucosidase Inhibitors: These agents (e.g., acarbose, miglitol) work by reducing the rate of polysaccharide digestion from the gut and have been shown to augment incretin secretion
This triple-agonist mechanism targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, creating synergistic effects that outperform conventional single-target medications